Citadel Advisors LLC Invests $101,000 in Invuity, Inc. (IVTY) Stock
Citadel Advisors LLC acquired a new position in shares of Invuity, Inc. (NASDAQ:IVTY) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 13,895 shares of the medical instruments supplier’s stock, valued at approximately $101,000. Citadel Advisors LLC owned 0.08% of Invuity at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of IVTY. FMR LLC increased its stake in Invuity by 0.5% during the 1st quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock worth $6,595,000 after acquiring an additional 4,264 shares during the period. Royce & Associates LP increased its stake in Invuity by 84.4% during the 1st quarter. Royce & Associates LP now owns 40,906 shares of the medical instruments supplier’s stock worth $325,000 after acquiring an additional 18,726 shares during the period. UBS Group AG increased its stake in Invuity by 53.4% during the 1st quarter. UBS Group AG now owns 13,200 shares of the medical instruments supplier’s stock worth $105,000 after acquiring an additional 4,594 shares during the period. Renaissance Technologies LLC bought a new position in Invuity during the 1st quarter worth $151,000. Finally, Lyon Street Capital LLC increased its stake in Invuity by 84.3% during the 1st quarter. Lyon Street Capital LLC now owns 727,032 shares of the medical instruments supplier’s stock worth $5,780,000 after acquiring an additional 332,593 shares during the period. Hedge funds and other institutional investors own 68.87% of the company’s stock.
WARNING: This story was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/10/16/citadel-advisors-llc-invests-101000-in-invuity-inc-ivty-stock.html.
A number of equities analysts have commented on IVTY shares. Piper Jaffray Companies restated a “buy” rating and set a $10.00 price objective on shares of Invuity in a research note on Wednesday, July 26th. Northland Securities restated a “buy” rating and set a $13.00 price objective on shares of Invuity in a research note on Tuesday, September 26th. ValuEngine upgraded Invuity from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research upgraded Invuity from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $11.00.
Invuity, Inc. (NASDAQ IVTY) opened at 8.80 on Monday. The company’s market cap is $150.04 million. The stock has a 50 day moving average price of $8.67 and a 200 day moving average price of $8.67. Invuity, Inc. has a 52 week low of $4.50 and a 52 week high of $12.51.
Invuity (NASDAQ:IVTY) last released its quarterly earnings results on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.07). The firm had revenue of $9.77 million during the quarter, compared to the consensus estimate of $10.30 million. Invuity had a negative return on equity of 140.69% and a negative net margin of 114.61%. On average, equities analysts forecast that Invuity, Inc. will post ($2.38) earnings per share for the current year.
Invuity Company Profile
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.